Effect of recombinant human erythropoietin on the rate of Na+,H+-exchange in erythrocytes from patients with chronic renal failure on hemodialysis

The study explores the effect of recombinant human erythropoietin and the rate of Na⁺,H⁺-exchange in erythrocytes from patients with chronic renal failure undergoing hemodialysis. The rate of Na⁺,H⁺-exchange in erythrocytes from patients was higher than in the control and remained unchanged after 24 months of treatment with erythropoietin. Therapy with recombinant human erythropoietin does not normalize the Na⁺,H⁺-exchange mechanism. It is concluded that factors underlying disturbances of ion transport in erythrocytes from uremic patients cannot be corrected with erythropoietin. Translated fromByulleten' Eksperimental'noi Biologii i Meditsiny, Vol. 124, No. 12, pp. 613–615, December, 1997